Cite
HARVARD Citation
Pearse, W. et al. (2021). A phase I/II trial of brentuximab vedotin plus rituximab as frontline therapy for patients with immunosuppression-associated CD30+ and/or EBV + lymphomas. Leukemia & lymphoma. 62 (14), pp. 3493-3500. [Online].